Keller ET - Search Results

1

Cyclooxygenase-2 promotes prostate cancer progression.

Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimito T, Namiki M, Mizokami A. Fujita H, et al. Among authors: keller et. Prostate. 2002 Nov 1;53(3):232-40. doi: 10.1002/pros.10152. Prostate. 2002. PMID: 12386924

2

Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.

Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T. Mizokami A, et al. Among authors: keller et. J Urol. 2000 Sep;164(3 Pt 1):800-5. doi: 10.1097/00005392-200009010-00053. J Urol. 2000. PMID: 10953159

3

Long-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells.

Harada S, Keller ET, Fujimoto N, Koshida K, Namiki M, Matsumoto T, Mizokami A. Harada S, et al. Among authors: keller et. Prostate. 2001 Mar 1;46(4):319-26. doi: 10.1002/1097-0045(20010301)46:4<319::aid-pros1039>3.0.co;2-c. Prostate. 2001. PMID: 11241555

4

Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.

Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET. Lin DL, et al. Among authors: keller et. Prostate. 2001 May 15;47(3):212-21. doi: 10.1002/pros.1065. Prostate. 2001. PMID: 11351351 Free article.

5

Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.

Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Zhang J, et al. Among authors: keller et. J Clin Invest. 2001 May;107(10):1235-44. doi: 10.1172/JCI11685. J Clin Invest. 2001. PMID: 11375413 Free PMC article.

6

Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice.

Smith PC, Keller ET. Smith PC, et al. Among authors: keller et. Prostate. 2001 Jun 15;48(1):47-53. doi: 10.1002/pros.1080. Prostate. 2001. PMID: 11391686 Free article.

7

Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells.

Fu Z, Dozmorov IM, Keller ET. Fu Z, et al. Among authors: keller et. Prostate. 2002 Apr 1;51(1):10-20. doi: 10.1002/pros.10056. Prostate. 2002. PMID: 11920953 Free article.

8

Characterization of C4-2 prostate cancer bone metastases and their response to castration.

Pfitzenmaier J, Quinn JE, Odman AM, Zhang J, Keller ET, Vessella RL, Corey E. Pfitzenmaier J, et al. Among authors: keller et. J Bone Miner Res. 2003 Oct;18(10):1882-8. doi: 10.1359/jbmr.2003.18.10.1882. J Bone Miner Res. 2003. PMID: 14584899 Free article.

9

The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.

Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET, Namiki M. Mizokami A, et al. Among authors: keller et. Cancer Res. 2004 Jan 15;64(2):765-71. doi: 10.1158/0008-5472.can-03-0130. Cancer Res. 2004. PMID: 14744796

10

Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein.

Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nör J, McCauley LK, Taichman RS, Keller ET. Dai J, et al. Among authors: keller et. Cancer Res. 2004 Feb 1;64(3):994-9. doi: 10.1158/0008-5472.can-03-1382. Cancer Res. 2004. PMID: 14871830

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

250 results

Search Page

Filters